Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, orthopedic devices giant Stryker (NYSE: SYK) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Stryker's business and see what CAPS investors are saying about the stock right now.

Stryker facts

Headquarters (Founded)

Kalamazoo, Mich. (1941)

Market Cap

$23.04 billion

Industry

Health-care equipment

Trailing-12-Month Revenue

$7.54 billion

Management

CEO Stephen MacMillan (since 2005)

CFO Curt Hartman (since 2009)

Return on Equity (Average, Past 3 Years)

18.7%

Cash/Debt

$2.89 billion / $996.6 million

Dividend Yield

1.2%

Competitors

Johnson & Johnson (NYSE: JNJ)

Smith & Nephew (NYSE: SNN)

Zimmer Holdings (NYSE: ZMH)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 98% of the 1,432 members who have rated Stryker believe the stock will outperform the S&P 500 going forward. These bulls include All-Star Jeffreyw, who is ranked in the top 5% of our community, and jerry665533.

Late last year , Jeffreyw tapped Stryker as a dependable long-term opportunity: "A leader in ortho products, should outperform as long as the quality of the products stand the test of a lifetime."

Over the past five years, in fact, Stryker has grown its bottom line at a solid rate of 15.1% annually. That's faster than listed rivals like Johnson & Johnson (3.1%) and Smith & Nephew (13.1%), let alone Zimmer's annual drop of 4.7%.

CAPS member jerry665533 expands on the Stryker outperform argument:

The global economic problems has slowed the pace of revenue and earnings growth of SYK, but as the world economies recover hospitals will increase the pace of purchasing of SYK top quality medical equipment and devices. Aging Baby Boomers will increase the demand for otrhopedic devices as well. In addition SYK will continue to expand via acquisition.

What do you think about Stryker, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Stryker is a Motley Fool Inside Value choice. Smith & Nephew is a Global Gains choice. Johnson & Johnson is a selection of Inside Value and Income Investor, and Motley Fool Options has recommended a diagonal call position on it. Alpha Newsletter Account, LLC owns shares of Johnson & Johnson. The Fool owns shares of Johnson & Johnson and Zimmer. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.